ChronoScale Corporation Common Stock (NASDAQ:CHRN) Share Price Passes Above 50-Day Moving Average – Should You Sell?

ChronoScale Corporation Common Stock (NASDAQ:CHRN)’s stock price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $11.15 and traded as high as $17.00. ChronoScale Corporation Common Stock shares last traded at $16.63, with a volume of 722,186 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a research note on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ChronoScale Corporation Common Stock presently has an average rating of “Reduce” and an average target price of $6.00.

ChronoScale Corporation Common Stock Stock Down 4.0%

The business has a 50-day simple moving average of $11.44 and a two-hundred day simple moving average of $8.61. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.03 and a current ratio of 1.55. The company has a market capitalization of $61.23 million, a price-to-earnings ratio of -3.20 and a beta of 0.86.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last posted its quarterly earnings data on Tuesday, April 28th. The company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.01). ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $4.29 million. As a group, equities analysts predict that ChronoScale Corporation Common Stock will post -0.1 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Daniel Asher acquired 15,540 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was bought at an average cost of $12.30 per share, with a total value of $191,142.00. Following the transaction, the insider owned 270,432 shares of the company’s stock, valued at $3,326,313.60. The trade was a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Trading of ChronoScale Corporation Common Stock

Hedge funds have recently added to or reduced their stakes in the stock. Roble Belko & Company Inc lifted its position in ChronoScale Corporation Common Stock by 104.5% during the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock worth $25,000 after acquiring an additional 1,195 shares during the period. Virtu Financial LLC acquired a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $57,000. Shay Capital LLC acquired a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $67,000. Geode Capital Management LLC lifted its position in ChronoScale Corporation Common Stock by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after acquiring an additional 10,281 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $198,000. 6.42% of the stock is owned by institutional investors and hedge funds.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.